logo
Share SHARE
FONT-SIZE Plus   Neg

CER Research Says Abbott's Response To Similac Test Results Irresponsible

Hong Kong-based CER Research Friday said Abbott Laboratories Inc.'s (ABT: Quote) response to the report released March 22 relating to the safety of the infant formula product Similac Stage 1 was "irresponsible." The report contained results which showed that the Abbott product, purchased in Hong Kong in December, failed two tests by a significant margin.

In its response, which, according to CER Research, was issued in Chinese, Abbott criticized the report for a lack of "scientific-ness, objectivity and fairness." CER Research's rebuttal claims that the results were obtained from "named and recognized laboratories and experts", adding that it has "no independent view" on the product. Further, CER Research said its attempts to contact Abbott were rebuffed.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Is it a 'personal life crisis' that led the Germanwings' co-pilot Andreas Lubitz to deliberately lowering the plane carrying 149 people to French Alps mountain? Police is investigating to find evidences to prove this suggestion. The Germanwings plane crash has spurred European airlines to implement stringent cockpit rules widely followed in the U.S., after it emerged a lone co-pilot forced the plane into its fatal descent, reports said on Thursday. Video-game retailer GameStop Corp. said Thursday after the markets closed that its fourth quarter profit rose 11% from last year, as better cost control helped offset a 5.6% decrease in sales. However, the company's quarterly earnings per share, excluding item, came in below analysts' expectations as did its quarterly sales.
comments powered by Disqus
RELATED NEWS
Trade ABT now with 
Follow RTT